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Available online 4 January 2017Reduced bone density and secondary osteoporosis, resulting in increased risk of fracture, is a significant compli-
cating factor in the inflammatory arthritides.While the exact etiology of systemic bone loss is not fully elucidated,
recent insights into the tumor necrosis factor super family (TNFSF) revealed a potential role for death receptor 3
(DR3/TNFRSF25) and one of its ligands, TNF-like protein 1A (TL1A/TNFSF15). The mechanisms by which DR3/
TL1A signalling modulates bone loss are unclear. We investigated the effect of DR3/TL1A signalling upon osteo-
clast-dependent chemokine andMMP production to unravel novel mechanismswhereby this pathway regulates
OC formation and OC-dependent bone resorption. Collagen induced arthritis (CIA) was established in DR3wt and
DR3ko mice, joints were sectioned and analysed histologically for bone damage while systemic trabecular bone
loss distal to the affected joints was compared bymicro-CT. Ablation ofDR3 protectedDBA/1mice against the de-
velopment and progression of CIA. In DR3ko, joints of the ankle and mid-foot were almost free of bone erosions
and long bones of mice with CIA were protected against systemic trabecular bone loss. In vitro, expression of
DR3 was confirmed on primary human CD14+ osteoclast precursors by flow cytometry. These cells were treated
with TL1A in osteoclast differentiation medium and TRAP+ osteoclasts, bone resorption, levels of osteoclast-as-
sociated chemokines (CCL3, CCL2 and CXCL8) andMMP-9measured. TL1A intensified human osteoclast differen-
tiation and bone resorption and increased osteoclast-associated production of CCL3 andMMP-9. Our data reveals
the DR3 pathway as an attractive therapeutic target to combat adverse bone pathology associated with inflam-
matory arthritis.We demonstrate that DR3 is critical in the pathogenesis ofmurine CIA and associated secondary
osteoporosis. Furthermore, we identify a novel mechanism by which the DR3/TL1A pathway directly enhances
human OC formation and resorptive activity, controlling expression and activation of CCL3 and MMP-9.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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MMP-91. Introduction
Increased prevalence of osteoporosis and decreased systemic bone
mineral density at areas distal from affected joints are complicating fac-
tors for patients diagnosed with several forms of inflammatory arthritis
(e.g. rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriat-
ic arthritis (PsA)) as it can lead to significant increased risk of fracture
[1–4]. The systemic inflammatory nature of these diseases is a substan-
tial contributory factor to bone loss [5]. Evidence from clinical studies
using biologics and non-steroidal anti-inflammatory drugs (NSAIDs)mmunity, School of Medicine,
nited Kingdom.
iamsas@cf.ac.uk (A.S. Williams).
re co-senior authors.
. This is an open access article underadvocate the key role of cytokines (e.g. TNF, IL-1β, IL-6) and PGE2 in or-
chestrating inflammation-associated bone damage [6–9]. However, in-
hibition or neutralization of these specific factors in patients does not
fully ameliorate the pathology associated with inflammatory arthritis,
as determined by the American College of Rheumatology improvement
criteria (ACR20) [10,11]. This suggests that unresolved progressive bone
disease observed during inflammatory arthritis may well be attributed
to additional factors. Members of the tumor necrosis factor superfamily
(TNFSF) such as LIGHT (TNFSF14), B lymphocyte stimulator (BLyS;
TNFSF13B), a proliferation-inducing ligand (APRIL; TNFSF13A) and
TNF-like protein 1A (TL1A; TNFSF15) are elevated in the serum and/or
synovial fluid of RA patients, potentially contributing to the bone pa-
thology associated with the musculoskeletal disease [12–14]. LIGHT,
BLyS and APRIL are capable of signalling through numerous transmem-
brane TNF receptor superfamily (TNFRSF) members to induce theirthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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membrane receptor, death receptor 3 (DR3; TNFRSF25) [15]. This
study focused on the role of DR3 in mediating pathological bone loss.
Death receptor 3 (DR3; TNFRSF25, TRAMP, LARD, Apo3 andWsl1) is
involved in the pathogenesis of multiple inflammatory conditions such
as inflammatory bowel disease, atherosclerosis, allergic lung inflamma-
tion and RA [14,16–20]. To date DR3 has two confirmed ligands, the
aforementioned TL1A, and progranulin (PGRN)/Atsttrin; which has
been demonstrated to inhibit TL1A activity [21]. While little is currently
known about the role of PGRN in DR3 modulation of bone more is
known about DR3/TL1A signalling. The potentially important role for
the DR3/TL1A pathway in regulating osteoclast (OC) formation and re-
sorptive activity has been evidenced inmurine and human studies. Car-
tilage damage and focal bone erosion were reduced or inhibited by DR3
or TL1A gene ablation in the murine models, antigen-induced arthritis
(AIA) and collagen-induced arthritis [22–24]. Furthermore, addition of
TL1A to human peripheral blood mononuclear cell (PBMC) cultures in
the presence of macrophage colony stimulating factor (MCSF) and re-
ceptor activator of nuclear factor kappa B ligand (RANKL) enhanced
OC formation [22]. These data imply an important role of DR3/TL1A in
modulating osteoclastogenesis and bone resorption, however, the un-
derlying mechanisms are unclear.
Signalling through the DR3/TL1A pathway following IFNγ priming
on human PBMC-derived CD14+ macrophages and the monocytic
THP-1 cell line induced expression of the chemokines CCL2 and CXCL8
[25,26]. The function of these chemokines is not limited to cell traffick-
ing as they also act as keymediators in themobilisation of OCprecursors
and OC differentiation. Indeed, elevated expression of the chemokines
CCL2, CCL3 and CXCL8 have been described in the serum and synovial
fluid of RA patients while in vitro they have been demonstrated to en-
hance RANKL-induced OC formation [27–32]. These chemokines how-
ever, have not previously been linked with DR3/TL1A dependent
osteoclast-associated bone damage. While chemokines play a role in
OC formation they are not directly involved in osteoclastic bone resorp-
tion. Dissolution of calcium by acidification of the resorption lacunae
and proteolysis of the organic matrix by matrix metalloproteinases
(MMPs), the cysteine proteinase cathepsin K and the metalloenzyme
tartrate resistant acid phosphatase (TRAP) results in bone degradation
[33–35]. MMP-9 specifically, is implicated in osteoclast bone resorption
[35,36]. Increased expression of MMP-9 has also been described in RA
patient serum and is correlated with the collagen degradation marker
hydroxyproline (OHPro), furthermore MMP-9 expression was reduced
in DR3ko joints undergoing AIA [24]. These initial findings suggest that
CCL2, CXCL8 andMMP-9 are important downstream effector molecules
by which DR3/TL1A signalling drives pathologic systemic bone loss ob-
served in the inflammatory arthritides.
In the present study we demonstrate a critical role for DR3 in the
pathogenesis of joint erosions in murine CIA and additionally reveal
that DR3 drives secondary osteoporosis at sites distal from the affected
small joints, usingDBA/1mice lacking theDR3 gene (DR3ko). In vitro, we
identify for the first time that DR3 is expressed on human CD14+ OC
precursors and differentiating OC. We report that TL1A directly in-
creases OC differentiation and resorptive activity in a concentration-de-
pendent fashion and that this is not through CCL2, but via elevated
expression of the osteoclastogenic chemokine CCL3 and enhanced acti-
vation of the gelatinase MMP-9.
2. Materials and methods
2.1. Animals and CIA
All animal experiments were undertaken in 6–8 week-old male
DBA/1DR3wt andDR3komice [37]. Procedureswere performed in accor-
dance with Home Office-approved licenses PPL 30/2361 and 30/2928
and complied with ARRIVE guidelines. Induction of CIA, assessment of
severity (paw scores) and inflammatory parameters (arthritis index)were carried out as previously described [24,38,39] (see supplementary
methods).2.2. Histological assessment of CIA joints
Architectural changes and inflammatory parameters caused by CIA
were assessed histologically in the left hind leg (DR3wt baseline n= 5,
DR3wt CIA n=15 and DR3ko baseline n=5, DR3ko CIA n=8) as previ-
ously described to assign an arthritis index score [38,39] (see supple-
mentary methods).2.3. Micro-computed tomography (μCT) analysis
In separate experiments, the right hind limbs (DR3wt baseline n=5,
DR3wt CIA n = 14 and DR3ko baseline n = 5, DR3ko CIA n = 8) were
scanned using a GE Explore Locus microcomputed tomography (μCT)
system at 20 μm voxel resolution obtained from 720 views. Beam
angle of increment was 0.5; beam strength 80 peak-kV and 450 μA.
Each blind run included DR3wt and DR3ko baseline and CIA bones, and
a calibration phantom to standardize grayscale values and maintain
consistency. Femoral bone analyses were performed in trabecular
bone (1% of total length proximal to the growth plate, extending
2 mm toward the diaphysis, excluding outer cortical bone). Trabecular
bone mineral content (BMC), bone volume/total volume (BV/TV), tra-
becular thickness (Tb·Th), spacing (Tb·Sp), and number (Tb·N) values
were computed by MicroView software (GE). Cortical measurements
were performed in a 2 × 2 × 2 mm cube midway down the bone.2.4. Human osteoclastogenesis assays and analysis of resorption pits
Ethical approval was obtained from the Medical/Dental School Re-
search Ethics Committee (09/21, Cardiff University, UK). Human pe-
ripheral blood mononuclear cells were isolated from healthy female
volunteers (n = 7) by density gradient centrifugation using
Histopaque-1077 (Sigma), and CD14+monocytes isolated by magnetic
cell sorting followingmanufacturer's instructions (Miltenyi Biotec, UK).
Cells (6.4 × 104; N95% CD14+ purity) were added to ivory discs in RPMI
supplemented with 10% FCS, 20 mM L-glutamine and 50 μg/ml Penicil-
lin/Streptomycin (RPMI-10). After 2 h at 37 °C 5% CO2, discs were trans-
ferred to 48-well plates and RPMI-10 with MCSF (5 ng/ml) added.
Media was replenished after 3 days and cells stained for DR3 after
7 days (classified as day 0 for OC assays). Media was replenished
every 3–4 days using RPMI-10 supplemented with MCSF (5 ng/ml),
RANKL (5 ng/ml), anti-polyHistidine (2.5 μg/ml) ± TL1A (10 or
100 ng/ml), all from R&D systems. Supernatants were stored at
−80 °C for further analysis. 3 discs per condition were stained for
TRAP on days 7, 10 and 14. Images of five random areas of the discs
were taken at ×10magnification using a BX41microscope and Camedia
C-3030 camera (Olympus, UK) and cropped to represent 1000 μm2
(Corel Paint Shop Pro, Corel, UK). The number of TRAP-positive multi-
nucleated cells and TRAP-negative/positive mononucleated cells were
counted and results reported per disc. For resorption pits, discs minus
cells and hematoxylin, were stained with toluidine, photographed and
analysed as above (see supplementary methods).2.5. Flow cytometry
Isolated human peripheral blood CD14+ monocytes (n = 7) and
cells isolated from OC cultures (n = 1 per time-point) were stained
with anti-DR3-PE (clone JD3) and anti-CD14-FITC (clone 61D3)
(eBioscience). Data were acquired on an Accuri C6 flow cytometer and
analysed with CFlow software (BD Biosciences).
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tant analysis
DR3wt andDR3ko CIA serum levels of IFNγ, TNFα, IL-2, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21 and IL-22 were analysed using
LEGENDplex Mouse Th Cytokine Panel (BioLegend, San Diego, CA) ac-
cording to the manufacturer's instructions. Levels of CCL2, CCL3,
CXCL8 and total MMP-9 in human osteoclastogenesis assay superna-
tants weremeasured using DuoSet kits (R&D Systems). TNFαwasmea-
sured in human osteoclastogenesis assay supernatants using an OptEIA
kit (BD Biosciences).2.7. Active MMP-9 zymogram
MMP-9 activity was determined by gelatine zymography following
manufacturer's instructions (Bio-rad) (see supplementary methods).
In vivo FX Pro and Molecular Imaging Software (Carestream) were
used to scan gels and visualize bands.2.8. Statistical analysis
Data are expressed as mean ± SEM, and statistical analysis (Mann-
Whitney U Tests for non-parametric, unpaired t-Tests for parametric
data, 1-way or 2-way analysis of variance (ANOVA)) performed using
GraphPad Prism software (GraphPad, San Diego, USA). p-Values of
≤0.05 were considered significant and p-values of ≤0.01 highly
significant.Fig. 1. Absence of DR3 protects against collagen-induced arthritis. CIA was induced inmale DR3
level of paw swelling. DR3wt CIA mice had significantly worse arthritis severity (p b 0.05) com
DR3ko CIA and DR3ko baseline controls. b) Summary data of pathology by an arthritis index d
index was significantly lower in DR3ko CIA compared to DR3wt CIA mice (p b 0.01); n = 5–1
following CIA induction: e = erosion; p = pannus formation; sh = synovial hyperplasia; si
performed with unpaired students t-test.3. Results
3.1. DR3ko mice are protected against focal bone erosion in response to col-
lagen-induced arthritis
Ablation of TL1A in a model of CIA has previously been demon-
strated to partially block inflammation and focal bone erosion asso-
ciated with the disease pathology [23]. The use of DR3ko mice to
investigate the pathogenesis of inflammation and focal bone erosion
in CIA however, has never been carried out. This is increasingly rele-
vant as novel non-TNFSF ligands for DR3 that impact on TL1A signal-
ling, such as PGRN, have recently emerged [21]. Significant increases
in arthritis severity, as determined by joint swelling and number of
affected joints, were observed in the DR3wt CIA cohort compared to
DR3wt baseline controls (p b 0.05). In contrast, arthritis severity in
the DR3ko CIA cohort did not differ significantly from the DR3ko con-
trols (Fig. 1a). Histological analysis (arthritis index) of hind limbs at
experimental endpoint further confirmed the importance of DR3 in
CIA pathology. While the DR3wt CIA mice exhibited a significantly
higher arthritis index compared to the DR3wt baseline (p b 0.001),
there was no significant difference observed in arthritis index be-
tween the DR3ko CIA mice compared to baseline mice. More impor-
tantly, a significantly lower arthritis index in DR3ko CIA compared
to DR3wt CIA mice (p b 0.01) was observed (Fig. 1b, c). Analysis of cy-
tokine expression in the serum of DR3wt and DR3ko CIA mice identi-
fied no significant difference in levels of IFNγ, TNFα or IL-6
(supplementary data Fig. 1). All other cytokines investigated were
below the limit of detection.wt and DR3komice bred onto a DBA/1 background. a) Arthritis severity was determined by
pared to the DR3wt baseline control. No significant difference was observed between the
etermined by scoring for erosion, cellular infiltrates, exudate and hyperplasia. Arthritis
5 mice per group. c) Representative micrographs of joints from DR3wt and DR3ko mice
= synovial infiltration; l = loss of joint space. Scale bar = 0.1 mm. Statistical analysis
Table 1
Femoral and cortical bone parameters.
Femoral
parameters
Baseline CIA
DR3wt DR3ko DR3wt DR3ko
BV/TV 18.96 ± 1.4 17.94 ± 1.9 5.95 ± 3.6a 10.21 ± 1.9ab
Tb·N (1/mm) 4.6 ± 0.2 4.9 ± 0.4 1.96 ± 0.3a 3.20 ± 0.2ab
Tb·Th (μm) 41.2 ± 2.0 36.2 ± 1.2 29.1 ± 1.3a 31.6 ± 2.1
Tb·Sp (mm) 0.18 ± 0.01 0.17 ± 0.02 0.73 ± 0.14a 0.29 ± 0.03b
Cortical parameters
Tt·Ar (mm2) 1.21 ± 0.01 1.24 ± 0.09 1.32 ± 0.02 1.32 ± 0.02
Ct·Ar (mm2) 0.80 ± 0.02 0.82 ± 0.07 0.91 ± 0.02 0.89 ± 0.03
Ma·Ar (mm2) 0.44 ± 0.02 0.41 ± 0.04 0.41 ± 0.01 0.42 ± 0.02
BMD (mg/cm3) 748 ± 64 775 ± 48 649 ± 49 685 ± 80
BMC (mg) 0.012 ± 0.001 0.014 ± 0.002 0.013 ± 0.000 0.012 ± 0.001
a - significant to base line, b - significant compared to DR3wt CIA.
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distal femur during collagen-induced arthritis
Generalized bone loss is a complicating factor in the pathogenesis of
inflammatory arthritis leading to increased risk of fracture [1,4]. We in-
vestigated whether absence of DR3 signalling could protect against sys-
temic trabecular bone loss, distal from affected small joints, in theFig. 2.Absence of DR3 protects against systemic bone loss associatedwith collagen-induced arth
and ii) severe arthritis ankle joints showing erosions. Arrows indicate areas of erosion. b) Re
trabecular BV/TV was determined by μCT. Both DR3wt (p b 0.0001) and DR3ko (p b 0.01) CIA
mice lost significantly more trabecular bone than DR3ko counterparts (p b 0.05). d) Represe
analysis performed with 1-Way ANOVA and Holm-Šídák post-test.murine CIAmodel. As ameasure of bonehealth, μCTwas used to analyse
the distal femur. Analysis of cortical bone parameters (Table 1) did not
identify any significant differences between baseline and CIA cohorts.
In contrast, the metaphyseal trabecular region displayed a significant
decrease in bone volume fraction (BV/TV) in both CIA DR3wt
(p b 0.0001) and CIA DR3ko (p b 0.01) mice compared to their baseline
controls (Fig. 2c). However, theDR3ko CIAmice had significantly greater
trabecular BV/TV than DR3wt CIA mice (DR3wt = 6.0 ± 1.1%, DR3ko =
10.2 ± 1.1%; p b 0.05). Similarly, CIA significantly decreased trabecular
number (Tb·N) in both DR3wt (p b 0.0001) and DR3ko (p b 0.05) mice,
but the decrease was greater in DR3wt CIA compared to DR3wt controls
(Table 1). Trabecular thickness (Tb·Th, p b 0.0001)was only significant-
ly decreased by CIA in DR3wt but not DR3ko mice. DR3ko CIA mice
showed significantly increased Tb·N (p b 0.05) and decreased Tb·Sp
(p b 0.05) compared to DR3wt CIA animals.
3.3. Expression of DR3 is induced by MCSF and the presence of a bone sub-
strate on human CD14+ osteoclast precursors
Ablation of DR3 signalling protected the ankle against CIA-in-
duced focal bone erosion and the distal femur from systemic bone
loss, implying that the DR3/TL1A pathway in mice promotes OC-de-
pendent bone pathology during inflammatory arthritis. Addition ofritis. CIAwas induced inmaleDR3wt andDR3komice. Representative images of a. i) control
presentative image of distal femoral trabecular region analysed by μCT. c) Distal femoral
mice significantly lost trabecular bone compared to relevant baseline control. DR3wt CIA
ntative μCT isosurface images. Scale bar = 1 mm. n = 5–14 mice per group. Statistical
Fig. 3. Expression of DR3 on human CD14+monocyte osteoclast precursors. CD14+monocytes were isolated from pre-menopausal females (n=7) and cultured on ivory discs for 7 days
inmedia+MCSF. DR3 expressionwasdeterminedbyflow cytometry. a)DR3wasnot detected on freshly isolated CD14+monocytes but confirmed after 7 days culture inMCSF (light grey
line = isotype, shaded peak = DR3). b) DR3 expression was maintained in cultures following addition of RANKL (black line = isotype, grey line = DR3).
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onstrated to enhance OC formation [22]. However, it is unclear
from these results whether the action of TL1A is through an indirect
mechanism, via CD4+ T cells, or a direct effect on the OC precursors.
To determine if TL1A can directly signal to human OC precursors, ex-
pression of DR3 was examined on isolated human peripheral blood
CD14+monocytes by flow cytometry. Samples were derived from fe-
males as osteoporosis and RA are more prevalent in women [40,41].
While DR3 expression was not detected on the surface of freshly iso-
lated CD14+ monocytes, it was up-regulated following culture for
7 days in MCSF on ivory discs indicating that TL1A could directly sig-
nal to the expanded population of osteoclast precursors (Fig. 3a).
Expression of DR3 was maintained in osteoclast-containing
cultures throughout the period of differentiation by RANKL and
MCSF (Fig. 3b). DR3 expression was not induced on cells cultured
on a glass substrate (supplementary data Fig. 2)Fig. 4. TL1A concentration-dependently increases osteoclast formation and osteoclast resorptio
ivory discs for 7 days inmedia+MCSF. Cells were differentiated for 7, 10 or 14 days in the prese
point cellswere stained for TRAP. a) TL1Ahadno effect on total cell number. b)A significant incr
TL1A cultures across the time-course. c) Representative images of TRAP stained i) control and i
OC. d) Discs were stained with toluidine blue and % area resorbed calculated. Significantly incre
cultures across the time-course compared to control. e) Representative day 14 confocal images
performed with 2-Way ANOVA and Bonferroni post-test.3.4. TL1A directly increases osteoclast formation from human CD14+ oste-
oclast precursors and upregulates osteoclast resorption in a concentration-
dependent manner
Having demonstrated that human CD14+ OC precursors express DR3
wenext sought to determine the direct effect of TL1A signalling onCD14+
precursor OC formation andOC resorptive activity. To assess the impact of
this, osteoclastogenesis assays using purified CD14+ monocytes on ivory
discs were carried out and the number of total cells (TRAP− and TRAP+)
and TRAP+ multinucleated cells per mm2 counted. At day 7, total cell
numbers in control cultures were 518 ± 33, comparable to those with
10 ng/ml (582±31) and 100 ng/ml TL1A (569±26) and did not change
significantly throughout the time-course (Fig. 4a). In contrast, addition of
TL1Ahad a significant concentration-dependent effect onOC formation as
did time, however no interaction between the two was observed (2-way
ANOVA: Time p b 0.05, TL1A p b 0.001). At days 10 and 14, OC numbersn. CD14+monocytes were isolated from pre-menopausal females (n=7) and cultured on
nce ofMCSF (M) and RANKL (R)± TL1A (T) at 10 ng/ml or 100 ng/ml. At experiment end-
ease inOCnumberswas observed in the 10ng/ml (p b 0.01) and the 100 ng/ml (p b 0.0001)
i) 100 ng/ml TL1A cultures at day 14. Scale bar = 250 μm. Arrows indicate multinucleated
ased resorption was observed in the 10 ng/ml (p b 0.0001) and 100 ng/ml (p b 0.01) TL1A
of i) control, ii) 10 ng/ml and iii) 100 ng/ml TL1A culture resorption pits. Statistical analysis
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tively) and significantly in the 100 ng/ml TL1A cultures (9 ± 1 and
12 ± 2 respectively; p b 0.05) when compared to cultures without TL1A
(8± 1 and 7± 1, respectively). This translated into a significant increase
in OC numbers in both the 10 ng/ml (p b 0.01) and 100 ng/ml TL1A cul-
tures across the time-course (p b 0.001; Fig. 4b, c). In the absence of
RANKL, TL1Ahadnoeffect on total cell numbers andwas unable to induce
osteoclast formation (supplementary data Fig. 3).
To determine the functional consequences of increased OC differentia-
tion, the % area resorbed by OC of the ivory discswasmeasured. At day 10
in cultures without TL1A, resorption was calculated as 0.9 ± 0.3%, which
increased in the 10 ng/ml (1.8 ± 0.4%) and 100 ng/ml (1.6 ± 0.4%)
TL1A cultures. At day 14, significantly increased resorption was observed
in 10 ng/ml (2.8 ± 0.4%; p b 0.01) and 100 ng/ml TL1A cultures (5.2 ±
1.6%; p b 0.001) compared to thosewithout TL1A (1.3±0.3%). This trans-
lated into significantly elevated resorption in the 10 ng/ml TL1A
(p b 0.001) and 100 ng/ml TL1A (p b 0.01) cultures across the time-course
(Fig. 4d, e).
3.5. TL1A signalling enhances RANKL-induced expression of the
osteoclastogenic chemokine CCL3
The mobilisation of OC precursors to sites of resorption and subse-
quent formation of OC is controlled by chemokines, including CCL2,
CXCL8 and CCL3 [31,42]. Addition of TL1A had no effect on expression
of CCL2 (Fig. 5a (i)) and CXCL8 (Fig. 5a (ii)) in osteoclast-containing cul-
tures. However, TL1A had a profound effect on levels of CCL3 (2-way
ANOVA: Time p b 0.0001, TL1A p b 0.05). Across the 14-day time-course
a significant overall increase in CCL3 secretion was detected in
100 ng/ml TL1A treated cells compared to untreated cultures
(p b 0.01; Fig. 5a (iii)). Expression of CCL3 had a positive and significant
correlationwithOCnumbers at day 7 (r=0.53, p b 0.01; Fig. 5b (i)), day
10 (r=0.51, p b 0.01; Fig. 5b (ii)) and day 14 (r=0.46, p b 0.05; Fig. 5b
(iii)). TL1A had no effect on CCL2, CXCL8 and CCL3 expression in cul-
tures without RANKL (supplementary data Fig. 4).
3.6. TL1A signalling increases RANKL-induced MMP-9 expression and
brings forward detection of active MMP-9 in osteoclast cultures
MMP-9, a gelatinase expressed by OC and their precursors, cleaves
collagen present in the organic matrix during osteoclastogenic bone
degradation [35]. In the present study TL1A was observed to increase
total MMP-9 expression (2-way ANOVA: Time p b 0.0001, TL1A
p b 0.001) with a significant increase detected across the 14-day time-
course in osteoclast cultures containing 100 ng/ml TL1A compared to
OC cultures containing 10 ng/ml TL1A (p b 0.05) and cultures without
TL1A (p b 0.001; Fig. 5c (i)). At day 14, total MMP-9 expression correlat-
ed positively with % area resorbed (r=0.49, p b 0.01; Fig. 5c (ii)). A gel-
atine zymogram was used to detect active MMP-9. The cleaved active
form of MMP-9 was not detected at the start of the OC cultures (day
0). From day 3 onwards active MMP-9was detected in OC cultures con-
taining 100 ng/ml TL1A compared to day 7 in cultures without TL1A
(Fig. 5d), suggesting that increasing levels of TL1A promotes activation
of MMP-9.
4. Discussion
Prior to this study DR3 has been shown to drive early cartilage de-
struction and bone pathology associated with the murine AIA model
of inflammatory arthritis [22,24]. However, this model does not recapit-
ulate the endogenous breach of tolerance that is typical of RA pathogen-
esis and as such is limited in its applicability to the disease [43]. To
address these shortcomings we utilized the murine model of CIA
which shares many immunological and pathological similarities with
RA: generation of autoantibodies toward self, breach of tolerance, sym-
metrical joint involvement, peripheral joints affected and systemicdevelopment of synovial hyperplasia, pannus formation and subse-
quent bone resorption [43–45]. In addition to DR3, TL1A, one of DR3’s
two confirmed ligands, has also been demonstrated to contribute to
the development and progression of focal bone erosions in murine
models of inflammatory arthritis [23], while increased levels are ob-
served in the serum and synovialfluid of patientswith inflammatory ar-
thritis [14]. These data highlight a significant role for DR3 inpathological
bone loss however, the mechanism through which DR3 signalling acts
upon bone-altering cells remains poorly defined. In the current study
we sought to identify the role of DR3 in the CIA model of inflammatory
arthritis-induced bone loss and reveal the mechanism by which DR3/
TL1A signalling affected human OC formation and resorptive activity.
We demonstrate for the first time that ablation of DR3 protects
against focal bone erosions in a CIA murine model of inflammatory ar-
thritis; the gold standard in vivomodel for RA studies.We further reveal
that absence of DR3 protected against systemic trabecular bone loss,
distal from the affected small joints. In an in vitro human system, we
show DR3 expression on CD14+ OC precursors and differentiating OC
and that TL1A can directly affect OC differentiation by increasing ex-
pression of the osteoclastogenic chemokine CCL3. TL1A also increased
OC resorptive activity, associatedwith enhanced expression and activa-
tion of MMP-9. All these effects are TNFα-independent as no TNFαwas
detected in cultures (Supplementary data Fig. 5).
The pathogenesis of inflammatory arthritis leads to focal bone ero-
sions of small joints and systemic bone loss, resulting in an increased
risk of fracture [4,46]. Prior to this study the role of DR3 in this pathology
had not been fully described, as the DR3-deletionmutant was not avail-
able on the murine DBA background. We describe for the first timemu-
rine CIA in the male DR3ko mouse; as the penetrance of this model is
very reproducible and less inclined to variability compared to female
mice [47]. Ablation of DR3 resulted in reduced arthritis severity, as de-
termined by reduced swelling and number of affected joints when com-
pared to the DR3wt. Furthermore DR3ko mice were significantly
protected against focal bone erosions. These results reveal a critical
role for DR3 in the pathogenesis of systemic joint damage in inflamma-
tory arthritis and support the findings observed in DR3ko mice on a
C57BL/6 background in the AIA inflammatory arthritis model [24].
This protection against focal bone erosion and inflammation is not due
to any baseline cellular abnormality in the myeloid cells from DR3ko
mice. Under canonical conditions, DR3ko osteoclastogenesis from bone
marrow-derived macrophages has been demonstrated to be compara-
ble to that of the DR3wt, while the addition of TL1A only boosted osteo-
clastogenesis in DR3wt cultures [22]. Furthermore, studies have shown
no significant difference in naïve T cell populations in the periphery or
lymphoid tissue [48]. Studies investigating both the TL1Ako in CIA and
DR3ko mouse in other inflammatory models revealed no significant dif-
ferences in the capacity to differentiate Treg (FoxP3+), Th1 and Th17
cells in relation to wildtype animals [23,49]. However, studies using
splenic T cells from wild-type and DR3ko mice identified that TL1A sig-
nalling through DR3 supported themaintenance of T cell IL-17A expres-
sion [50], the expansion of effector T cells at sites of disease [49],
expansion of T cells following viral infection [51] and expansion of T
cells following bacterial infection [52]. This suggests that the DR3/
TL1A pathway is not required for baseline maintenance of cell profiles
and number but under inflammatory conditions maintains the signal
to drive their expansion. In addition to identifying a role for DR3 in reg-
ulating joint damage we revealed a novel role in systemic bone loss.
Analysis of both DR3wt and DR3ko CIA mice showed a reduction in fem-
oral trabecular bone compared to their non-CIA controls, however, the
amount of trabecular bone loss in DR3ko mice was significantly less
than their DR3wt counterparts. This suggests that CIA-induced trabecu-
lar bone loss is DR3-dependent, though further experiments would be
required to determine the relative contribution of DR3 onmyeloid, lym-
phoid and stromal cells. This result reveals a previously unappreciated
effect of DR3 signalling in distal systemic bone loss associated with the
inflammatory arthritides [1–4]. Interestingly, no difference in serum
Fig. 5. TL1A concentration-dependently increases expression of the osteoclastogenic chemokine CCL3 and gelatinase MMP-9. CD14+ monocytes were isolated from pre-menopausal
females (n= 7). Cells were cultured on ivory discs for 7 days in media + MCSF and further differentiated for 7, 10 or 14 days in the presence of MCSF (M) and RANKL (R) ± TL1A (T)
at 10 ng/ml or 100 ng/ml. Culture supernatants were collected at indicated time-points and tested for a) i) CCL2, ii) CXCL8 and iii) CCL3. Significantly increased CCL3 levels were
detected across the time-course in 100 ng/ml TL1A cultures compared to control (p b 0.01). No differences were observed in CCL2 and CXCL8 levels. b) CCL3 levels significantly
correlated with OC numbers at (i) day 7, (ii) day 10 and (ii) day 14. c) i) Significantly increased total MMP-9 expression was observed in the 100 ng/ml TL1A cultures across the time-
course compared to control (p b 0.0001) and 10 ng/ml TL1A cultures (p b 0.05). ii) Levels of total MMP-9 significantly correlated with % area resorbed at day 14. d) Levels of pro- and
active-MMP-9 in cultures were determined by gelatine zymography (n = 4). Representative zymograms for control (MR) and 100 ng/ml TL1A (MRT) cultures. Pro-MMP-9 was
detected in both cultures across the time-course. Active MMP-9 was first detected at day 3 in the 100 ng/ml TL1A OC cultures and day 7 in control cultures. Samples run in duplicate.
Statistical analysis performed with 2-Way ANOVA and Spearman correlation.
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mice at experimental endpoint. This suggests that the protection from
both focal and systemic bone loss observed in the DR3komice is directly
dependent on the ablation of DR3 signalling and is not a consequence of
subsequent changes in levels of other pro-inflammatory cytokines. The
importance of these findings are increased following the discovery of a
second ligand for DR3, PGRN/Atsttrin, which signals negatively through
DR3 inhibiting the effects of TL1A [21]. While earlier studies by Bull,
Williams et al. [22] and Wang et al. [23] identified that treatment of
CIA using a TL1A antagonist, or ablation of TL1A, protected against
focal bone erosion it was unknown whether this was due to decreased
DR3 signalling or increased DR3/PGRN signalling.
While DR3/TL1A signalling has been implicated in pathological bone
loss, its mechanism of action was not certain. Bull, Williams et al. [22]
showed that addition of exogenous TL1A to PBMC cultures enhanced
OC formation, but it was unclearwhether the effect of TL1Awas directly
on the OC precursors (CD14+ monocytes) or via an intermediary cell
type (e.g. CD4+ T cells). An indirect effect would be in keeping with re-
ports that TL1A enhances CD4+ Th17 differentiation in RA patients,
maintains Th17 numbers, with IL-17 subsequently enhancing OC differ-
entiation [50,53,54]. In the present study, CD14+ monocytes isolated
from human pre-menopausal females were utilized as a source of oste-
oclast precursors; as females are significantlymore prone to developing
osteoporosis and RA [40,41]. Furthermore, under canonical conditions
pre-menopausal females have been shown to exhibit similar levels of
osteoclastogenesis tomatchedmales thus no hormonal effects were ex-
pected [55]. DR3 was not found on circulating CD14+ monocytes, in
agreement with previous reports [25]. However, its expression was in-
duced following culture in the presence of MCSF on an ivory substrate,
but not glass. This suggests that signals supplied by the local environment
and substrate are important in DR3 induction; with signalling by Ca2+
through the calcium sensing receptor (CaSR) potentially key in the induc-
tion of DR3 expression on osteoclast precursors [56]. However, these data
reveal that TL1A can signal directly throughDR3 onCD14+OCprecursors.
Studies into the effect of TL1A signalling on effector T cells have dem-
onstrated that it drives proliferation [49,51]. Here, addition of TL1A to
CD14+monocyte OC cultures had no effect on precursor expansion, indi-
cating differential effects depending on cell type. Irrespective, TL1A had a
concentration-dependent effect on eventual OC numbers asmeasured by
TRAP staining, implying action through induction of OC differentiation.
This is the first time in a primary human system that TL1A has been
shown to act directly on OC precursors to enhance OC formation and is
consistent with effects observed in murine RAW264.7 macrophage cells
[21]. In addition to increasing OC formation, in the current study TL1A
was observed to have a concentration-dependent effect on resorptive ac-
tivity consistent with previous reports [22,57]. However, it was not clear
from these studies whether the increase in resorptive function was a
result of the increase in OC numbers or as a result of an increase in the
resorptive capacity of the OC. To investigate the underlying mechanisms
which resulted in the increased OC formation and resorption, culture
supernatants were analysed for soluble mediators.
Osteoclast differentiation is the process by whichmononuclear cells
migrate and undergo fusion into the multinucleated OC and is con-
trolled in part by chemokines. The chemokines CCL2, CXCL8 and CCL3
have all been shown to have roles in osteoclastogenesis; CCL2-deficient
mice exhibit significantly reduced OC numbers while addition of
exogenous CCL2, CXCL8 or CCL3 to OC cultures enhances RANKL-in-
duced OC formation [29–31]. Interestingly, CCL3-null mice and anti-
CCL2 treated rats are protected against bone damage in models of CIA,
further highlighting the importance of these chemokines in OC pathol-
ogy [58,59]. In consensus with the studies by Kang et al. [25] and Su et
al. [60], CCL2 production was not affected by the addition of TL1A.
Contradictory to these papers however, we report that TL1A had no ef-
fect on CXCL8 expression. This difference may be due to: use of THP-1
cells; higher concentrations of TL1A and; co-stimulation with IFNγ in
the Kang et al. [25] and Su et al. [60] studies. Instead, we found CCL3expression increased in a concentration-dependent manner implying
that this is a downstream target of DR3/TL1A signalling. CCL3 levels
also correlated with OC numbers across the time-course, but were
unaffected by the addition of TL1A alone suggesting that TL1A effects
on CCL3 are RANKL-dependent. Perhapsmore significantlywith regards
to human disease, increased concentrations of CCL3 are present in
serum and synovial fluid from RA patients and in serum of PsA patients
[27,61,62].
To determine the mechanism for the increased bone resorption the
gelatinase MMP-9 was investigated. MMP-9 has been shown to have a
role in bone resorption [35,36]. Increased expression of MMP-9 has
also been identified in RA patients [63] while in murine models of in-
flammatory arthritis a milder pathology has been observed in MMP-9
KO mice [64]. Furthermore, MMP-9 is induced by TL1A signalling in
THP-1 cells [25], has been found to be reduced in DR3ko joints undergo-
ingAIA [24] and levels of the active form are reduced inDR3ko osteoclast
cultures (supplementary data Fig. 6), implying that MMP-9 is a key
downstream target of DR3/TL1A signalling. In the present study, TL1A
increased levels of total MMP-9, which correlated significantly with
levels of resorption. However, for MMP-9 to be functionally active it
must be cleaved into its active form [65]. TL1A brought forward the
time-point at which active MMP-9 was first observed. Whether this is
due to the increased amount of total MMP-9, or TL1A promoting cleav-
age of MMP-9 to its active form, remains to be seen. This and the fact
that TL1A-dependent MMP-9 release from primary myeloid cells may
require additional priming events [24], indicate that the relationship be-
tween TL1A and MMP-9 is complex and requires further investigation.
In summary, we have identified for the first time in vitro, that the
osteoclastogenic chemokine CCL3 and the gelatinase MMP-9 are in-
duced downstream of DR3/TL1A signalling on primary human CD14+
OC precursors. We show that TL1A concentration-dependently in-
creases OC formation and resorptive activity by increasing expression
of CCL3 and expression and activation of MMP-9. Combined with our
in vivo CIA data we demonstrate the importance of DR3 signalling in
the progression of pathologic OC activity associated with inflammatory
arthritis-induced focal bone erosion and secondary osteoporosis.
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